Literature DB >> 29962186

Estimation of age-dependent decrease in blastocyst euploidy by next generation sequencing: development of a novel prediction model.

Sandro C Esteves1,2, José F Carvalho3, Ciro D Martinhago4, Augusto A Melo4, Fabiola C Bento5, Peter Humaidan6,7, Carlo Alviggi8.   

Abstract

BACKGROUND: We developed a model to estimate the female age-dependent decrease in blastocyst euploidy and the impact of blastocyst cohort size on the likelihood of having at least one euploid blastocyst for transfer.
METHODS: Retrospective analysis of 1296 trophectoderm biopsies by next-generation sequencing analysis from 436 infertile couples undergoing intracytoplasmic sperm injection and preimplantation genetic testing for aneuploidy. A logistic regression model was fit to the data. The dependent and independent variables were embryo genetic status and female age, respectively. The method of fitting was quadratic on age, and the model was validated with cross validation by a data splitting technique.
RESULTS: The decrease in the probability of blastocyst euploidy follows an age-dependent binomial distribution, progressing with every year of female age, from 1.2% to 24.5% in 28-44 years-old women (P<0.0001). The minimum number of blastocysts needed to obtain at least one euploid blastocyst for transfer was computed for different probabilities and female ages. At the age of 28 years, a total of three blastocysts is required to obtain at least one euploid blastocyst with 90% probability, whereas it is 4, 5, 6, 9, 16 and 29 for ages 35, 37, 39, 41, 43, and 45, respectively.
CONCLUSIONS: A novel prediction model estimates the probability of blastocyst euploidy and the number of blastocysts required to obtain at least one euploid embryo for transfer. This new resource based on f emale age and blastocyst cohort size will aid clinicians counsel and plan treatment of infertile couples undergoing IVF/ICSI.

Entities:  

Mesh:

Year:  2018        PMID: 29962186     DOI: 10.23736/S0031-0808.18.03507-3

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  17 in total

Review 1.  Evolution of the World Health Organization semen analysis manual: where are we?

Authors:  Sandro C Esteves
Journal:  Nat Rev Urol       Date:  2022-05-06       Impact factor: 16.430

Review 2.  Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why.

Authors:  Sandro C Esteves; Matheus Roque; Giuliano M Bedoschi; Alessandro Conforti; Peter Humaidan; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-17       Impact factor: 5.555

Review 3.  Management Strategies for POSEIDON Groups 3 and 4.

Authors:  Thor Haahr; Carlos Dosouto; Carlo Alviggi; Sandro C Esteves; Peter Humaidan
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-11       Impact factor: 5.555

4.  A Novel Predictive Model to Estimate the Number of Mature Oocytes Required for Obtaining at Least One Euploid Blastocyst for Transfer in Couples Undergoing in vitro Fertilization/Intracytoplasmic Sperm Injection: The ART Calculator.

Authors:  Sandro C Esteves; José F Carvalho; Fabiola C Bento; Jonathan Santos
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-28       Impact factor: 5.555

5.  Efficacies of different ovarian hyperstimulation protocols in poor ovarian responders classified by the POSEIDON criteria.

Authors:  Fei Li; Tian Ye; Huijuan Kong; Jing Li; Linli Hu; HaiXia Jin; Yingchun Su; Gang Li
Journal:  Aging (Albany NY)       Date:  2020-05-29       Impact factor: 5.682

6.  COVID-19 and assisted reproductive technology services: repercussions for patients and proposal for individualized clinical management.

Authors:  Carlo Alviggi; Sandro C Esteves; Raoul Orvieto; Alessandro Conforti; Antonio La Marca; Robert Fischer; Claus Y Andersen; Klaus Bühler; Sesh K Sunkara; Nikolaos P Polyzos; Ida Strina; Luigi Carbone; Fabiola C Bento; Daniela Galliano; Hakan Yarali; Lan N Vuong; Michael Grynberg; Panagiotis Drakopoulos; Pedro Xavier; Joaquin Llacer; Fernando Neuspiller; Marcos Horton; Matheus Roque; Evangelos Papanikolaou; Manish Banker; Michael H Dahan; Shu Foong; Herman Tournaye; Christophe Blockeel; Alberto Vaiarelli; Peter Humaidan; Filippo M Ubaldi
Journal:  Reprod Biol Endocrinol       Date:  2020-05-13       Impact factor: 5.211

7.  Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Alessandro Conforti; Sandro C Esteves; Peter Humaidan; Salvatore Longobardi; Thomas D'Hooghe; Raoul Orvieto; Alberto Vaiarelli; Danilo Cimadomo; Laura Rienzi; Filippo Maria Ubaldi; Fulvio Zullo; Carlo Alviggi
Journal:  Reprod Biol Endocrinol       Date:  2021-06-21       Impact factor: 5.211

8.  Editorial: POSEIDON's Stratification of 'Low Prognosis' Patients in ART: The WHY, the WHAT, and the HOW.

Authors:  Sandro C Esteves; Claus Yding Andersen; Robert Fischer; Peter Humaidan; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-29       Impact factor: 5.555

9.  Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.

Authors:  Sandro C Esteves; Hakan Yarali; Lan N Vuong; José F Carvalho; İrem Y Özbek; Mehtap Polat; Ho L Le; Toan D Pham; Tuong M Ho; Peter Humaidan; Carlo Alviggi
Journal:  Hum Reprod       Date:  2021-07-19       Impact factor: 6.918

Review 10.  Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations.

Authors:  Antoine Abu-Musa; Thor Haahr; Peter Humaidan
Journal:  Int J Mol Sci       Date:  2020-03-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.